current test updates

When changes are made to testing requirements, methodologies, etc., Wisconsin Diagnostic Laboratories (WDL) strives to keep you informed as soon as possible so we can provide the highest quality service to you. 

 

To open documents, simply click on the link for more information.

 

Effective May 20, 2020, Wisconsin Diagnostic Laboratories (WDL) has updated the names for Routine Culture and Aerobic/Anaerobic Culture.

 

Effective May 20, 2020, Wisconsin Diagnostic Laboratories (WDL) is updating urine drug screening.

 

Effective April 10, 2020, the reference range and the Heparin Therapeutic Range for Activated Partial Thromboplastin Time (PTT) will change.

 

Effective March 24, 2020, Wisconsin Diagnostic Laboratories will replace aging instruments in the Chemistry laboratory with new instruments.

 

Effective February 2020, Wisconsin Diagnostic Laboratories will begin offering an immunohistochemistry PD-L1 stain and a Mismatch Repair Panel. Bringing this testing in-house considerably improves turnaround time.

 

Clarification regarding Fetal Cell Detection (Kleihauer Stain) Reporting Change

 

Effective Jan. 29, 2020, WDL is updating syphilis testing.

 

Effective Jan. 29, 2020, WDL will begin in-house testing for the anti-epileptic drug CLOBAZAM (ONFI) and its active metabolite DESMETHYLCLOBAZAM. Bringing this test in-house will significantly improve turnaround time.

 

Effective Jan. 15, 2020, WDL will offer a new test for assessment of vitamin B12 status, VITAMIN B12 REFLEX TO METHYLMALONIC ACID. This new reflex test will be the preferred test for assessment of vitamin B12 status, replacing parallel testing of vitamin B12 and methylmalonic acid. This change aligns with current best-practices, which recommend methylmalonic acid testing only as follow up in cases of borderline deficient or low vitamin B12.